文献速递胸部肿瘤放疗中枢神经肿瘤放疗姑息放疗与转移瘤

高危转移性NSCLC预防性颅脑照射的长期结局:PRoT-BM最终分析

Long‑term outcomes of prophylactic cranial irradiation in high‑risk metastatic NSCLC: Final PRoT‑BM analysis.
PubMed 文献 · Radiother Oncol · 2026-03-12

中位随访77.3个月,PCI使脑转移风险降低60%(HR 0.40),并延长总生存(30.51 vs 19.23个月,HR 0.46),未增加远期神经认知毒性。

要点

  • PCI显著降低高危转移性NSCLC的5年脑转移累积发生率(51.7% vs 78.3%,HR 0.40)。
  • PCI组中位OS延长至30.51个月,对照组19.23个月(HR 0.46,p=0.002)。
  • EGFR突变患者敏感性分析一致获益(HR 0.57),48个月时PCI组幸存者MMSE评分更稳定。

核心结论

  • 在高危转移性NSCLC中,PCI持久降低脑转移发生率、延长总生存并保持神经认知功能,但需多中心III期试验确认。

主要发现

  • 中位随访77.3个月,PCI组5年脑转移累积发生率为51.7%,对照组为78.3%(HR 0.40;95% CI 0.21-0.78;p=0.007)。
  • PCI组中位OS为30.51个月,对照组为19.23个月(HR 0.46;95% CI 0.28-0.74;p=0.002)。
  • EGFR突变患者敏感性分析(每组n=32)显示一致获益(HR 0.57;95% CI 0.33-0.99;p=0.045)。
  • 5年软脑膜癌病累积发生率PCI组11.5%、对照组17.4%(HR 0.51;p=0.29)。
  • MMSE评估的神经认知功能至24个月两组无差异;48个月时PCI组幸存者评分更稳定(p=0.006),无进行性放疗相关神经毒性证据。

临床怎么用

  • 对于高危转移性NSCLC且无基线中枢神经系统病变的患者,PCI(25 Gy/10次)可考虑用于降低脑转移风险并可能改善生存。
  • 治疗决策需结合EGFR突变状态及患者对神经认知功能的顾虑,并注意该证据来自单中心II期试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIM: To report long-term outcomes of prophylactic cranial irradiation (PCI) versus observation in high-risk advanced non-small-cell lung cancer (NSCLC). METHODS: PRoT-BM is an open-label, single-center, phase II randomized trial. Adults with stage IIIB/IV NSCLC at high risk for brain metastases (BM) and no baseline CNS disease were assigned (1:1) to PCI (25 Gy/10 fractions) plus standard therapy or standard therapy alone. The primary endpoint was 24-month cumulative BM incidence; this update evaluates 5-year BM incidence, overall survival (OS), leptomeningeal carcinomatosis, and long-term neurocognitive function (NCF). RESULTS: Eighty-four patients were randomized (May 2012-December 2017); 81 comprised the efficacy cohort (PCI, n = 38; control, n = 43). At median follow-up of 77.3 months, PCI reduced BM risk by 60% (HR 0.40; 95% CI 0.21-0.78; p = 0.007), with 60-month cumulative incidence of 51.7% versus 78.3%. Median OS was 30.51 versus 19.23 months (HR 0.46; 95% CI 0.28-0.74; p = 0.002); a sensitivity analysis restricted to EGFR-mutant patients (n = 32 per arm) confirmed a consistent benefit (HR 0.57; 95% CI 0.33-0.99; p = 0.045). Leptomeningeal events were infrequent (5-year incidence 11.5% vs 17.4%; HR 0.51; p = 0.29). MMSE-assessed NCF showed no between-arm differences through 24 months; at 48 months, PCI-treated survivors maintained more stable scores than controls (p = 0.006), with no evidence of progressive radiation-related neurotoxicity. CONCLUSIONS: In high-risk metastatic NSCLC, PCI durably reduced BM incidence, prolonged OS, and preserved neurocognitive function over six years of follow-up. These single-center phase II findings warrant multicenter phase III confirmation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Cabrera-Miranda L, Maldonado F, Rios-Garcia E, et al. Long‑term outcomes of prophylactic cranial irradiation in high‑risk metastatic NSCLC: Final PRoT‑BM analysis. Radiother Oncol. 2026. PMID: 41831620. doi:10.1016/j.radonc.2026.111483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。